Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer

Lung cancer is the most common cause of death from cancer, and 5-year survival in patients with lung cancer varies depending on stage at diagnosis[1,2]. Although the 5-year survival rate of stage I lung cancer could reach as high as 68 ～92%[3], only 20.8% of patients with stage I lung cancer were diagnosed in China. Currently, LDCT screening is recommended for high-risk individuals of early detection of stage I lung cancer[4]. The National Lung Screening Trial (NLST) demonstrated a 20% relative reduction in lung cancer mortality for annual screening over three years with LDCT to chest radiography[5].

Source: Lung Cancer - September 28, 2021 Category: Cancer & Oncology Authors: Min Li, Chunliu Zhang, Shichao Deng, Li Li, Shiqing Liu, Jing Bai, Yaping Xu, Yanfang Guan, Xuefeng Xia, Lunquan Sun, David P. Carbone, Chengping Hu Source Type: research